Hormones and Endocrine Drugs

Used as a progesterone

Desonide is a glucocorticoid drug with anti-inflammatory, anti allergic, antipruritic and reducing exudation effects; It can reduce and prevent the reaction of tissue to inflammation, eliminate the fever, redness and swelling caused by local non infectious inflammation, so as to reduce the performance of inflammation; It has the immunosuppressive effect of preventing or inhibiting cellular immune response and inhibiting primary immune response.

Leigh Larry Dean is a new highly effective and selective two peptide peptide -4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.

Norethisterone, a derivative of 19 demethyltestosterone, is an oral progesterone. Its progesterone activity is 4 times higher than that of progesterone, and its estrogen and androgen activities are weak. It can inhibit the secretion of hypothalamic luteinizing releasing hormone (LHRH). By stimulating the anterior pituitary, it can reduce the sensitivity of the body to LHRH, so as to block the release of gonadotropin and inhibit ovulation. After oral administration of this product for 0.5 ~ 4 hours, the blood concentration can reach the peak, and the half-life is 5 ~ 14 hours. Most of the metabolites are discharged from the body through the kidney.

Epalrestat is a carboxylic acid derivative and a noncompetitive and reversible aldose reductase inhibitor used for the treatment of diabetic neuropathy, which is one of the most common long-term complications in patients with diabetes mellitus. It reduces the accumulation of intracellular sorbitol which is believed to be the cause of diabetic neuropathy, retinopathy and nephropathy It is well tolerated, with the most commonly reported adverse effects being gastrointestinal issues such as nausea and vomiting, as well as increases in certain liver enzymes. Chemically, epalrestat is unusual in that it is a drug that contains a rhodanine group. Aldose reductase is the key enzyme in the polyol pathway whose enhanced activity is the basis of diabetic neuropathy. Aldose reductase inhibitors (ARI) target this enzyme. Out of the many ARIs developed, ranirestat and fidarestat are in the trial stage. Others have been discarded due to unacceptable adverse effects or weak efficacy. Epalrestat is the only ARI commercially available. It is easily absorbed into the neural tissue and inhibits the enzyme with minimum side effects.